JP2017537613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537613A5 JP2017537613A5 JP2017523216A JP2017523216A JP2017537613A5 JP 2017537613 A5 JP2017537613 A5 JP 2017537613A5 JP 2017523216 A JP2017523216 A JP 2017523216A JP 2017523216 A JP2017523216 A JP 2017523216A JP 2017537613 A5 JP2017537613 A5 JP 2017537613A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- human
- protein
- muna
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004999 Messenger RNA Proteins 0.000 claims description 19
- 229920002106 messenger RNA Polymers 0.000 claims description 19
- 239000000178 monomer Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 claims description 8
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 8
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 8
- 229960000027 human factor IX Drugs 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 229920000401 Three prime untranslated region Polymers 0.000 claims description 3
- 229920001405 Coding region Polymers 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 8
- 241001367079 Una Species 0.000 claims 4
- 102000018511 hepcidin family Human genes 0.000 claims 4
- 108060003558 hepcidin family Proteins 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 201000009673 liver disease Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 2
- 229920001320 Leader sequence (mRNA) Polymers 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000002730 additional Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 229960005486 vaccines Drugs 0.000 claims 2
- 230000036499 Half live Effects 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001086 cytosolic Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004962 mammalian cells Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 239000012096 transfection reagent Substances 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 description 15
- 108090000394 Erythropoietin Proteins 0.000 description 15
- 229940105423 erythropoietin Drugs 0.000 description 15
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001404 mediated Effects 0.000 description 5
- 108020003635 Untranslated Regions Proteins 0.000 description 3
- 229920000146 Untranslated region Polymers 0.000 description 3
- 102100006624 F9 Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 210000003494 Hepatocytes Anatomy 0.000 description 2
- 101700049847 REL2 Proteins 0.000 description 2
- 101710030576 Y10A Proteins 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960004222 factor IX Drugs 0.000 description 2
- 102000020437 poly(A) binding proteins Human genes 0.000 description 2
- 108091022174 poly(A) binding proteins Proteins 0.000 description 2
- PYNVSZMFFVWFQA-NOMGDLSISA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(1-hydroxyethyl)oxolan-2-yl]-3H-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](C(O)C)O[C@H]1N1C(NC(N)=NC2=O)=C2N=C1 PYNVSZMFFVWFQA-NOMGDLSISA-N 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 210000000474 Heel Anatomy 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 101710043536 crp79 Proteins 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101700072390 pAbp Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Description
Claims (40)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074046P | 2014-11-02 | 2014-11-02 | |
US62/074,046 | 2014-11-02 | ||
PCT/US2015/058534 WO2016070166A2 (en) | 2014-11-02 | 2015-11-01 | Messenger una molecules and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017537613A JP2017537613A (en) | 2017-12-21 |
JP2017537613A5 true JP2017537613A5 (en) | 2018-12-06 |
JP6728156B2 JP6728156B2 (en) | 2020-07-22 |
Family
ID=55858532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017523216A Active JP6728156B2 (en) | 2014-11-02 | 2015-11-01 | Messenger UNA molecule and its use |
Country Status (6)
Country | Link |
---|---|
US (2) | US20160130567A1 (en) |
EP (1) | EP3212793B1 (en) |
JP (1) | JP6728156B2 (en) |
AU (1) | AU2015338923B2 (en) |
CA (1) | CA2966527C (en) |
WO (1) | WO2016070166A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7423522B2 (en) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | Polynucleotide encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017218524A1 (en) * | 2016-06-13 | 2017-12-21 | Rana Therapeutics, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
HUE059843T2 (en) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
CN110636866A (en) | 2016-12-19 | 2019-12-31 | 萨勒普塔医疗公司 | Exon skipping oligomer conjugates for muscular dystrophy |
SG10202100491QA (en) | 2016-12-19 | 2021-02-25 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
WO2018127382A1 (en) * | 2017-01-03 | 2018-07-12 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
WO2018160592A1 (en) | 2017-02-28 | 2018-09-07 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
US11939600B2 (en) | 2017-05-31 | 2024-03-26 | Arcturus Therapeutics, Inc. | Compositions and methods for treating phenylketonuria |
KR102636537B1 (en) * | 2017-05-31 | 2024-02-15 | 울트라제닉스 파마수티컬 인코포레이티드 | Treatment for Glycogen Storage Disease Type III |
US11015204B2 (en) * | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
EA201991450A1 (en) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY |
WO2019067975A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
US20200254002A1 (en) | 2017-09-28 | 2020-08-13 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
JP2020536058A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | Combination therapy to treat muscular dystrophy |
WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
CA3084061A1 (en) | 2017-12-20 | 2019-06-27 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
TW202020153A (en) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | Exon skipping oligomers for muscular dystrophy |
WO2020118115A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
WO2020123574A1 (en) | 2018-12-13 | 2020-06-18 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
EP3955966A1 (en) | 2019-04-18 | 2022-02-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
US20230136960A1 (en) * | 2020-03-19 | 2023-05-04 | Nature's Toolbox, Inc. | Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same |
WO2021205077A1 (en) | 2020-04-09 | 2021-10-14 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
CN112023062A (en) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | Method for inhibiting allergic reactions using soluble IgE receptors |
WO2023055774A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511423A (en) * | 1993-06-10 | 1996-12-03 | ジェネティック セラピー,インコーポレイテッド | Adenovirus vector for treatment of hemophilia |
EP1319082B1 (en) * | 2000-09-18 | 2005-11-16 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
DK2578685T3 (en) | 2005-08-23 | 2019-06-03 | Univ Pennsylvania | RNA CONTAINING MODIFIED NUCLEOSIDES AND METHODS OF USE THEREOF |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
US8454948B2 (en) * | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
EP2089424B1 (en) * | 2006-12-06 | 2015-07-01 | JCR PHARMACEUTICALS Co., LTD. | Method for production of human erythropoietin |
US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
MX2009012568A (en) * | 2007-05-22 | 2009-12-08 | Mdrna Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes. |
CN102695525B (en) | 2009-07-31 | 2016-01-20 | 埃泽瑞斯公司 | For the RNA with the combination of unmodified and modified nucleotide of protein expression |
EP3318635A1 (en) * | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013101690A1 (en) * | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
DK2830595T3 (en) * | 2012-03-29 | 2019-12-02 | Translate Bio Inc | IONIZABLE CATIONIC LIPIDS |
AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
AU2013281355B2 (en) * | 2012-06-28 | 2018-04-05 | Caldera Health Ltd | Targeted RNA-seq methods and materials for the diagnosis of prostate cancer |
EP2968397A4 (en) * | 2013-03-12 | 2016-12-28 | Moderna Therapeutics Inc | Diagnosis and treatment of fibrosis |
WO2014160243A1 (en) * | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
CN105873902B (en) | 2013-11-18 | 2019-03-08 | 阿克丘勒斯治疗公司 | Ionizable cation lipid for RNA delivery |
KR20220100078A (en) | 2014-01-31 | 2022-07-14 | 팩터 바이오사이언스 인크. | Methods and products for nucleic acid production and delivery |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
US11241505B2 (en) | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
-
2015
- 2015-11-01 CA CA2966527A patent/CA2966527C/en active Active
- 2015-11-01 JP JP2017523216A patent/JP6728156B2/en active Active
- 2015-11-01 EP EP15855964.1A patent/EP3212793B1/en active Active
- 2015-11-01 US US14/929,366 patent/US20160130567A1/en not_active Abandoned
- 2015-11-01 WO PCT/US2015/058534 patent/WO2016070166A2/en active Application Filing
- 2015-11-01 AU AU2015338923A patent/AU2015338923B2/en active Active
-
2017
- 2017-11-07 US US15/806,096 patent/US10815463B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7423522B2 (en) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | Polynucleotide encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017537613A5 (en) | ||
US20210403944A1 (en) | Circular RNA For Translation In Eukaryotic Cells | |
JP7189943B2 (en) | Non-Integrating DNA Vectors for Genetic Modification of Cells | |
US20180179526A1 (en) | Method and Medicament For Inhibiting The Expression of A Given Gene | |
EP2877213B1 (en) | Inducible dna binding proteins and genome perturbation tools and applications thereof | |
AU2013242403A1 (en) | Artificial nucleic acid molecules | |
TW202043249A (en) | Methods and compositions for editing rnas | |
AU2015338968A1 (en) | Delivery of negatively charged proteins using cationic lipids | |
CA3039733A1 (en) | Compositions and methods for the treatment of myotonic dystrophy | |
CN111108208A (en) | Compositions comprising healds and uses thereof | |
JP2006518204A (en) | Targeting system based on transposon | |
JP2022122910A (en) | ENGINEERED Cas9 SYSTEMS FOR EUKARYOTIC GENOME MODIFICATION | |
US20240084330A1 (en) | Compositions and methods for delivering cargo to a target cell | |
JP2021184745A (en) | Novel minimal utr sequences | |
KR20000029120A (en) | Episomally replicating vector, its preparation and use | |
US20230061936A1 (en) | Methods of dosing circular polyribonucleotides | |
JP2023538964A (en) | Synthetic miniaturized CRISPR-CAS (CASMINI) system for eukaryotic genome engineering | |
JP2023531384A (en) | Novel OMNI-59, 61, 67, 76, 79, 80, 81 and 82 CRISPR Nucleases | |
JP2023522020A (en) | CRISPR inhibition for facioscapulohumeral muscular dystrophy | |
US11072782B2 (en) | Construct for epigenetic modification and its use in the silencing of genes | |
KR102545913B1 (en) | Composition for improving efficiency and product purity on base editing comprising inhibitors of histone deacetylase and uses thereof | |
WO2022140560A1 (en) | In vitro assembly of anellovirus capsids enclosing rna | |
JP2024502620A (en) | Ribozyme-activated RNA constructs and uses thereof | |
ES2958832T3 (en) | Plasmid containing a sequence coding for an mRNA with a cleaved poly(A) tail | |
EP2739738B1 (en) | Use of integrase for targeted gene expression |